Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadwood Capital Reduces Futher Questcor Pharmaceuticals Inc (QCOR)

In its filing with the Securities and Exchange Commission, Neal C. Bradsher’s Broadwood Capital has disclosed further reducing its stake in Questcor Pharmaceuticals Inc (NASDAQ:QCOR). The filing showed that the fund sold 205,000 shares in one deal at a price of $83.96 per share. Currently, the fund owns around 2.05 million shares.

Questcor Pharmaceuticals Inc (NASDAQ:QCOR)

Headquartered in Anaheim, California, Questcor Pharmaceuticals Inc (NASDAQ:QCOR) is a biotechnology company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The firm primarily offers H.P.Acthar Gel, a treatment for acute exacerbations of multiple sclerosis in adults. In February 2014, Broadwood Capital sold 50,000 shares of Questcor Pharmaceuticals Inc (NASDAQ:QCOR). The fund also sold 20,000 shares January.

Recently, Mallinckrodt PLC (NYSE:MNK) agreed to acquire Questcor Pharmaceuticals Inc (NASDAQ:QCOR) in a transaction valued at about $5.6 billion. The deal, subject to customary closing conditions, is expected to be completed in the third calendar quarter of 2014, according to a statement.

In its latest 13F, Broadwood Capital revealed holding around 2.80 million shares of Questcor Pharmaceuticals Inc (NASDAQ:QCOR). James E. Flynn’s Deerfield Management held an $82 million stake, which contains 1.51 million shares. Another investor, Adage Capital Management, managed by Phill Gross and Robert Atchinson, disclosed holding 1.33 million shares in its latest 13F.

Broadwood Capital is a New York City-based fund with an equity portfolio worth around $497.3 million. At the beginning of 2014, the fund disclosed raising its stake in BioTime Inc. (NYSEMKT:BTX) to 9.52 million shares, from some 9.02 million held previously.

Among the largest stakes revealed by Broadwood in its latest 13F, is STAAR Surgical Company (NASDAQ:STAA), in which the fund holds a $111.5 million stake, which amasses 6.89 million shares. Another one is Monster Beverage Corp (NASDAQ:MNST), in which Broadwood owns around 1.60 million shares, worth $108.4 million.

Disclosure: none

Recommended Reading:

RA Capital Reports New 5.8% Position In Recently Public Versartis Inc (VSAR)

Anchorage Advisors Sells Over 1 Million Shares In Central Pacific Financial Corp. (CPF)

Jeffrey Smith, Starboard Value are Bullish on Unwired Planet Inc (UPIP)

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!